Indivumed GmbH, a Hamburg, Germany-based physician-led, integrated global oncology company, received a €40m loan.
The European Investment Bank (EIB) provided the financial resources.
The EIB funding will allow the company to develop and validate new assays biomarker for the Biobank business and technology platforms.
Led by Hartmut Juhl, MD, Founder and CEO, Indivumed provides tumour data and a biobank to third parties such as biopharmaceutical companies and research institutes.
The EIB funding together with additional private investments will also enable the company to create a ‘Global Cancer Database Solution’ which would support cancer researchers worldwide by providing access to data from cancer patients, as well as bioinformatic tools to better understand complex cancer data.